Savara Announces Participation in Upcoming Healthcare Investor Conferences
30 1월 2025 - 6:05AM
Business Wire
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage
biopharmaceutical company focused on rare respiratory diseases,
today announced that members of its management team will be
attending two upcoming healthcare investor conferences and
participating in fireside chats at each.
Guggenheim SMID Cap Biotech Conference, February 5-6,
2025 Fireside Chat: February 5th, 10:00am ET/7:00am
PT
Oppenheimer 35th Annual Healthcare Life Sciences Conference,
February 11-12, 2025 Fireside Chat: February 11th,
8:00am ET/5:00am PT
The live webcasts and subsequent replays will be available on
the “Events & Presentations” section of the Company’s corporate
website at https://savarapharma.com/investors/events-presentations/
and will be archived for 90 days.
About Savara
Savara is a clinical stage biopharmaceutical company focused on
rare respiratory diseases. Our lead program, MOLBREEVI*, is a
recombinant human granulocyte-macrophage colony-stimulating factor
(GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar
proteinosis (aPAP). MOLBREEVI is delivered via an investigational
eFlow® Nebulizer System (PARI Pharma GmbH) specifically developed
for inhalation of a large molecule. Our management team has
significant experience in rare respiratory diseases and pulmonary
medicine, identifying unmet needs, and effectively advancing
product candidates to approval and commercialization. More
information can be found at www.savarapharma.com, X: @SavaraPharma
and LinkedIn.
*MOLBREEVI is the FDA and EMA conditionally accepted trade name
for molgramostim inhalation solution. It is not approved in any
indication.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250129351153/en/
Media and Investor Relations
Contact Savara Inc. Temre Johnson, Executive Director,
Corporate Affairs ir@savarapharma.com
Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
Savara (NASDAQ:SVRA)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025